2-Bromo-3-methyl-4-(1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl)butanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-Bromo-3-methyl-4-(1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl)butanoic acid
• 英文别名: 2-bromo-3-methyl-4-(1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl)butanoic acid
• 化学式: C₁₅H₂₅BrO₂
• 分子量: 317.26
• InChiKey: MYWMVJHLBSKURK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Tamper-resistant pharmaceutical dosage forms and process for making same
  申请人：ExxPharma Therapeutics LLC

  公开号：US10010620B2

  公开（公告）日：2018-07-03

  A process for the preparation of an erodible tamper-resistant dosage form that comprises a therapeutic agent-substrate complex embedded in a thermo-formable matrix, such that the complex includes at least one therapeutic agent bound to at least one substrate to form the therapeutic agent-substrate complex. The at least one substrate is being selected from a polyelectrolyte, an organic counter-ion, a pharmacologically inert organic component of a prodrug, an inclusion compound and an inorganic adsorbent; and the thermo-formable matrix includes one or more thermoplastic polymers and optionally at least one pharmaceutical additive. The dosage form provides resistance to intentional or unintentional tampering such as chewing, crushing and grinding, and volatilization.

  一种用于制备可侵蚀防篡改剂型的工艺，该剂型包括嵌入热成型基质中的治疗剂-基质复合物，该复合物包括至少一种治疗剂与至少一种基质结合以形成治疗剂-基质复合物。至少一种基质选自聚电解质、有机反离子、原药的药理学惰性有机成分、包涵化合物和无机吸附剂；热成型基质包括一种或多种热塑性聚合物，以及可选的至少一种药物添加剂。该剂型可防止有意或无意的篡改，如咀嚼、粉碎和研磨以及挥发。
• Tamper-Resistant Pharmaceutical Dosage Forms
  申请人：ExxPharma Therapeutics LLC

  公开号：US20150064250A1

  公开（公告）日：2015-03-05

  The invention provides a tamper-resistant dosage form including a therapeutic agent-substrate complex embedded in a thermo-formable matrix; such that the complex includes at least one therapeutic agent bound to at least one substrate to form the therapeutic agent-substrate complex. The at least one substrate is being selected from the group consisting of a polyelectrolyte, an organic counter-ion, a pharmacologically inert organic component of a prodrug, an inclusion compound and an inorganic adsorbent; and the thermo-formable matrix includes one or more thermoplastic polymers and optionally at least one pharmaceutical additive.
• Tamper Resistant Dosage Form Composition And Process Of Making The Same
  申请人：Ghebre-Sellassie Isaac

  公开号：US20150064251A1

  公开（公告）日：2015-03-05

  A tamper-resistant dosage form including a therapeutic agent-substrate complex embedded in a thermo-formable matrix; such that the complex includes at least one therapeutic agent bound to at least one substrate to form the therapeutic agent-substrate complex. The at least one substrate is being selected from the group consisting of a polyelectrolyte, an organic counter-ion, a pharmacologically inert organic component of a prodrug, an inclusion compound and an inorganic adsorbent; and the thermo-formable matrix includes one or more thermoplastic polymers and optionally at least one pharmaceutical additive.
• Tamper-Resistant Pharmaceutical Dosage Forms and Process for Making Same
  申请人：ExxPharma Therapeutics LLC

  公开号：US20160175454A1

  公开（公告）日：2016-06-23

  A process for the preparation of an erodible tamper-resistant dosage form that comprises a therapeutic agent-substrate complex embedded in a thermo-formable matrix, such that the complex includes at least one therapeutic agent bound to at least one substrate to form the therapeutic agent-substrate complex. The at least one substrate is being selected from a polyelectrolyte, an organic counter-ion, a pharmacologically inert organic component of a prodrug, an inclusion compound and an inorganic adsorbent; and the thermo-formable matrix includes one or more thermoplastic polymers and optionally at least one pharmaceutical additive. The dosage form provides resistance to intentional or unintentional tampering such as chewing, crushing and grinding, and volatilization.
• US9770514B2
  申请人：——

  公开号：US9770514B2

  公开（公告）日：2017-09-26